News Headlines Article

Highly selective startup snags $45M to take on deadly lung disease
San Francisco Chronicle

While a handful of companies are targeting a deadly and baffling lung-scarring disease, the CEO of a Redwood City spinout from UCSF believes his company has some key advantages: a well-defined target and a group of scientific founders that are among the best in the world. Pliant Therapeutics Inc. scored $45 million in a Series A round from Third Rock Ventures in its quest to stop — and perhaps even reverse — idiopathic pulmonary fibrosis, or IPF. The company hopes to push its lead drug into the clinic in 2018.